Media Release
Mar 04, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
Leading the first clinical approval of an in vivo gene editing drug mediated by LNP in China
Share
LATESTNEWS
-
CDE Clears IND Application for Therapeutic Candidate Targeting ATTR
Mar 18, 2024
-
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
Feb 15, 2024
-
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
Dec 17, 2023
